{"filings":[{"id":527196,"accession_number":"0000885590-26-000057","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2026-05-19T20:18:10+00:00","items":["5.07"],"status":"ready","headline":"Bausch Health elects Eiry W. Roberts as new director; say-on-pay passes at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eiry W. Roberts elected to board with 196,972,752 votes for, 2,585,679 withheld; broker non-votes 79,859,606.","All other incumbent directors re-elected; vote tallies range from 183.9M to 196.8M for.","Say-on-pay advisory vote passed: 189,432,400 for, 9,588,417 against, 537,614 abstain.","PricewaterhouseCoopers LLP appointed as auditor for 2027 fiscal year with 276,774,936 for, 2,643,100 withheld."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99446,"accession_number":"0000885590-26-000051","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch Health reports Q1 2026 results; detailed figures not available in excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filing references earnings press release for quarter ended March 31, 2026, issued April 29, 2026.","The full press release (Exhibit 99.1) is referenced but not included in the provided text.","No revenue, EPS, segment data, or guidance figures can be extracted from the filing body alone.","Without the exhibit content, no specific financial metrics or trends can be summarized."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":2524000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115443,"accession_number":"0001193125-26-085755","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bausch Health changes CEO and EVP PSU settlement from stock to cash for 2023 awards","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["1,137,862 PSUs for CEO Thomas Appio amended to cash settlement instead of stock upon March 3, 2026 vesting.","137,922 PSUs for EVP Seana Carson similarly changed; cash equal to market price on vesting date.","Cash settlement amount based on closing price of BHC common stock on March 3, 2026.","Changes made via amended award agreement (Appio) and new agreement (Carson) under Canadian tax law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115442,"accession_number":"0000885590-26-000020","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch Health reports Q4/FY2025 results; press release content not available in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Quarterly earnings release furnished under Item 2.02; no specific financial data provided in this excerpt.","The filing includes only the SEC form header and exhibit marker; actual numbers are missing.","Investors should refer to the full press release on the company's website or EDGAR for results.","No guidance, segment data, or other material items described in the provided text."],"consensus_eps_estimate":null,"consensus_eps_actual":0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":10266000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115441,"accession_number":"0000885590-26-000008","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bausch Health issues press release on Phase 3 RED-C trial; no details in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Press release announces results of global Phase 3 RED-C program for amorphous-rifaximin in liver cirrhosis.","Trial evaluated primary prevention of hepatic encephalopathy; specific endpoint outcomes not provided in filing summary.","Filing includes only the 8-K body; the attached Exhibit 99.1 text was not included for analysis.","Item 7.01 Regulation FD disclosure; information is furnished, not filed, per standard practice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115440,"accession_number":"0000885590-26-000005","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"Bausch Health to reaffirm FY2025 guidance at high end at JPM conference","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Presentation at 44th Annual J.P. Morgan Healthcare Conference on Jan 14, 2026 at 3:45 p.m. PT.","Management expects to reaffirm full year 2025 guidance at the higher end of the range for Bausch Health ex B+L.","No specific financial figures or updated guidance were disclosed in this filing.","Live webcast and replay available on investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115439,"accession_number":"0000950103-26-000052","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Bausch + Lomb closes $2.8B term loan refinancing, reduces margins, extends maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $2.802B Replacement Term Loans maturing 2031 to refinance existing term B loans due 2028 and 2031.","Interest margin reduced by 0.50% (vs prior 2031 loans) and 0.25% (vs 2028 loans); SOFR+3.75% or ABR+2.75%.","Amortization at 1.00% per annum, first installment payable June 30, 2026.","Effective maturity extension of the 2028 loans from September 2028 to January 2031."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131870,"accession_number":"0000885590-25-000059","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bausch Health completes $1.6B exchange of senior secured notes, pledges additional 60% of Bausch + Lomb","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.6B aggregate principal of new 10.00% Senior Secured Notes due 2032 in exchange for outstanding 4.875% and 11.00% notes due 2028.","New notes are fungible with existing $4.4B of 10.00% Senior Secured Notes due 2032 issued April 2025.","Pledged additional 26.5M Bausch + Lomb common shares, increasing pledge from ~52.5% to ~60% of outstanding common shares.","Total collateral now includes 211.96M Bausch + Lomb shares as security for both existing and new notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131869,"accession_number":"0000885590-25-000057","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch Health completes debt exchange for up to $1.6B in 10.00% senior secured notes due 2032","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["Exchange offers expired Dec. 23, 2025; old 4.875% and 11.00% senior secured notes due 2028 exchanged for new notes.","New 10.00% Senior Secured Notes due 2032 issued by subsidiary 1261229 B.C. Ltd. with up to $1.6B aggregate principal.","Final tender results not disclosed in filing; press release attached as Exhibit 99.1 with no additional detail provided.","Exchange extends near-term maturities but increases interest cost for the 4.875% notes while reducing cost for the 11% notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131868,"accession_number":"0000950103-25-016089","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch + Lomb refinances $2.8B term loans; margin cut, maturity extended to 2031","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$2.802B new Replacement Term Loans to refinance existing term B loans due 2028 and 2031.","Applicable margin reduced by 0.50% (to 3.75%+SOFR) for Third Amendment loans and 0.25% (to 2.75%+ABR) for First Incremental loans.","Maturity extended for First Incremental loans from Sep 29, 2028 to Jan 15, 2031; Third Amendment loans unchanged at 2031.","Transaction expected to close in Q1 2026, subject to conditions; no assurance of completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131867,"accession_number":"0000885590-25-000054","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch Health announces early results of debt exchange offers; press release details not provided","summary_kind":"llm","event_type":"debt","confidence":"low","bullets":["Company offered to exchange outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for up to $1.6B new 10.00% Senior Secured Notes due 2032.","Early results measured as of 5:00 p.m. NYC time on December 8, 2025.","New notes to be issued by indirect wholly-owned subsidiary 1261229 B.C. Ltd.","Confidential exchange offer memorandum dated November 24, 2025 governs the offers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131866,"accession_number":"0001193125-25-291998","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch Health launches exchange of up to $1.6B notes, offers 10% senior secured notes due 2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offers to exchange 4.875% and 11.00% Senior Secured Notes due 2028 for new 10.00% Senior Secured Notes due 2032; up to $1.6B aggregate principal.","Participating holders of ~$1.545B (46% outstanding) have agreed to tender under Transaction Support Agreement signed Nov 24, 2025.","Early tender deadline Dec 8, 2025; holders receive $100 early premium per $1,000 principal; total consideration up to $1,020/$887.50.","New notes will be fungible with existing $4.4B 10.00% Notes due 2032 issued April 2025, same CUSIP (except Reg S).","Offers expire Dec 23, 2025; acceptance subject to target ratio (52.6% 11.00% notes, 47.4% 4.875% notes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131865,"accession_number":"0000885590-25-000048","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch Health announces Q3 2025 results; exhibit with details not provided","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release for Q3 ended September 30, 2025 issued on October 29, 2025.","No specific financial figures (revenue, EPS, segments) are included in the filing body.","Exhibit 99.1 referenced but not appended; results are unknown to the analyst.","Common shares trade under ticker BHC on NYSE and Toronto Stock Exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":7470000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131864,"accession_number":"0000885590-25-000044","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bausch Health shareholders approve Amended and Restated Rights Plan at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Oct 7, 2025; shareholders voted to ratify the Rights Plan Agreement.","Votes: 178,244,775 in favor, 40,130,633 against.","Rights Plan originally adopted Apr 14, 2025 and amended Aug 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148451,"accession_number":"0001193125-25-200869","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch Health completes acquisition of DURECT for $1.75/share plus CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer closed with 62% of DURECT shares (19.98M) validly tendered and accepted.","Price: $1.75 per share in cash plus one contingent value right per share.","CVRs provide up to $350M aggregate milestone payments (net of retention bonuses).","BHC Lyon merged into DURECT; DURECT now a wholly-owned subsidiary of Bausch Health Americas.","Transaction consummated on September 11, 2025 after all conditions satisfied."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148450,"accession_number":"0001193125-25-181736","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["1.02","5.02","7.01","9.01"],"status":"ready","headline":"Bausch Health directors Icahn and Miller resign after Icahn Group stake falls; Paulson increases holding to 19.13%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brett M. Icahn and Steven D. Miller resigned from the board effective August 14, 2025, upon termination of the Director Appointment and Nomination Agreement.","The agreement terminated because the Icahn Group's net long position in BHC shares fell below the required threshold.","Paulson Capital Inc. and affiliates acquired the Icahn Group's 34,721,118 common shares, increasing its beneficial ownership to 19.13% of outstanding shares.","John A. Paulson, Board Chairperson, expressed confidence in Bausch Health's value and business prospects.","Resignations were not due to any disagreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148449,"accession_number":"0000885590-25-000030","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch Health files Q2 2025 earnings release; financial figures not included in provided text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued July 30, 2025 for quarter ended June 30, 2025.","No specific financial data (revenue, EPS, segment results) available in the filing excerpt.","Full press release attached as Exhibit 99.1 but content not provided for summary.","Ticker BHC listed on NYSE and Toronto Stock Exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":4789000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148448,"accession_number":"0001193125-25-167131","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch Health to acquire DURECT for $1.75/share ($63M upfront) plus up to $350M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Bausch Health will pay $1.75/share cash upfront, valuing DURECT at ~$63M, with up to $350M in additional net sales milestone payments.","The upfront price represents a ~191% premium to DURECT's 30-day VWAP and ~217% premium to the July 28 closing price.","DURECT's lead asset larsucosterol has FDA Breakthrough Therapy Designation for alcoholic hepatitis, with planned Phase 3 trial.","Transaction expected to close in Q3 2025, subject to majority tender and customary conditions.","Acquisition complements Bausch's hepatology pipeline alongside ongoing rifaximin SSD Phase 3 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148447,"accession_number":"0001193125-25-163860","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Bausch Health appoints Michael Goettler and Sandra Leung to Board, effective July 22, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expands from 10 to 12 members with the addition of two new directors.","Michael Goettler, former Viatris CEO, joins Talent & Compensation and Science & Technology Committees.","Sandra Leung, former BMS EVP & General Counsel, joins Nominating & Corporate Governance Committee.","Both appointees have extensive pharmaceutical industry leadership experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148446,"accession_number":"0001193125-25-157612","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Bausch Health appoints Steven Lee as SVP, Controller and Chief Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective July 14, 2025; Lee will oversee financial reporting and corporate controllership.","Annual base salary of $450,000; target cash bonus 50% of salary; sign-on equity $175,000 in RSUs.","Previously VP/CFO at BrandSafway and VP, Corporate Controller/CAO at Mohawk Industries.","Sign-on bonus must be repaid if Lee resigns within first year; without-cause termination provides one-year salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167261,"accession_number":"0001193125-25-149731","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Bausch + Lomb closes upsized €675M senior secured notes and $2.325B term loan refinancing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €675M senior secured floating rate notes due 2031 at 3-month EURIBOR+3.875%.","Entered $2.325B term B loan facility due 2031; amortization 1% p.a., first payment Sept 2025.","Established new $800M revolver due 2030, replacing $500M facility; covenant levels increased to max 5.75x first lien net leverage.","Proceeds used to repay existing revolver and refinance term A and B loans due 2027.","Third Amendment provides additional transaction flexibility and modified financial covenant levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167260,"accession_number":"0000950103-25-007605","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch + Lomb prices €675M secured notes, upsized; new term loan $2.325B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Priced €675M senior secured floating rate notes due 2031 at 99.5% of principal; offering upsized from €600M.","Also upsized New Term B Loan Facility to $2.325B from $2.2B, accruing at Term SOFR + 4.25%.","Proceeds to repay existing revolver and refinance term A and B loans due 2027.","Closing expected June 26, 2025; notes offering not contingent on new credit facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167259,"accession_number":"0000950103-25-007190","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch + Lomb launches €600M senior secured notes offering and $2.2B term loan refinancing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Subsidiaries launch €600M senior secured floating rate notes.","Also pursuing $2.2B new term B loan facility and $800M revolver.","Proceeds to repay existing revolver and fully refinance term A and B loans due 2027.","Notes offering not contingent on closing of new credit facilities.","Notes guaranteed by Bausch + Lomb and certain subsidiaries, secured on first-priority basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167258,"accession_number":"0001193125-25-123366","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bausch Health enters standstill-like pacts with Icahn, Paulson, Kavanagh limiting activism","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Icahn Group, John Paulson, and Sarah Kavanagh each signed letter agreements with Bausch Health on May 20, 2025.","If a group engages in a 'Specified Action' (proxy contest, solicitation, >19.99% stake), members must resign from both BHC and B+L boards.","BHC agrees to vote its B+L shares in favor of each group's designee if nominated to B+L board and to offer new committee seats.","Icahn Group irrevocably waives right to designate replacement directors under B+L DANA upon resignation.","Agreements terminate upon a director's resignation from BHC board, with some provisions surviving until next B+L annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167257,"accession_number":"0001193125-25-120802","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bausch Health CAO John Barresi resigns, effective June 2; CFO Charhon to serve as interim CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John S. Barresi resigns as SVP, Controller and CAO effective June 2, 2025.","Resignation is not due to any disagreement with the company on operations, policies, or accounting practices.","Company initiates search for permanent CAO; CFO Jean-Jacques Charhon will assume additional CAO role upon Barresi's departure.","Charhon has been CFO since July 2024; no family relationships or material transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167256,"accession_number":"0000885590-25-000022","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bausch Health shareholders reelect all 10 directors, approve say-on-pay and ESPP at May 13 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected with over 199 million votes for each; broker non-votes ~56.3M.","Advisory vote on executive compensation approved: 199,584,790 for, 13,233,305 against, 1,525,913 abstain.","2025 Employee Stock Purchase Plan approved: 209,243,257 for, 3,660,841 against, 1,439,910 abstain.","PricewaterhouseCoopers LLP appointed as independent auditor for 2026: 266,669,018 for, 4,014,796 withheld."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167255,"accession_number":"0000885590-25-000018","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch Health Q1 2025 earnings release filed; figures not available in excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Q1 2025 results announced via press release; financial data not included in the provided text.","No revenue, EPS, or segment details are extractable from this filing excerpt.","Full results are expected in the attached Exhibit 99.1, which is not appended here."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":2259000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167254,"accession_number":"0001193125-25-080728","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["1.01","3.03","7.01","9.01"],"status":"ready","headline":"Bausch Health adopts shareholder rights plan (poison pill) effective April 14, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved shareholder rights plan on April 14, 2025; one right attaches to each common share outstanding.","Plan not adopted in response to any specific takeover bid or proposal; Board is unaware of any pending threat.","Rights become exercisable at a substantial discount if a person acquires 20%+ of common shares (subject to Permitted Bid exception).","Plan subject to TSX acceptance and shareholder ratification within six months; if not ratified, it terminates.","Similar to other Canadian public company shareholder rights plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167253,"accession_number":"0001193125-25-075911","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bausch Health closes $4.4B 10% secured notes due 2032 and $3B term loan facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed offering of $4.4B aggregate principal of 10.000% senior secured notes due 2032 via subsidiary 1261229 B.C. Ltd.","Entered new $3B 5.5-year senior secured term loan and $500M 5-year revolving credit facility; proceeds used to repay existing debt.","Notes and credit facilities secured by first-priority liens on assets including 52.5% equity interest in Bausch + Lomb (BLCO).","Mandatory redemption provisions triggered by sale of BLCO shares or dividends over $50M; change-of-control puts at 101%.","Credit agreement includes financial covenant: Blended First Lien Leverage Ratio not exceed 4.25:1.00 (5.75:1.00 post-Xifaxan exclusivity step-up)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184603,"accession_number":"0000885590-25-000013","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch Health prices $4.4B 10% senior secured notes due 2032, upsized from $4.0B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Bausch Health priced $4.4B aggregate principal of 10.000% senior secured notes due 2032, upsized from $4.0B.","Offering expected to close April 8, 2025; net proceeds to repay existing credit agreement and redeem all Existing Notes.","Company received commitments for $500M new 5-year revolver and $3.0B 5.5-year term loan B facility.","Conditional redemption notices delivered for five series of Existing Notes; redemption conditioned on financing closing.","No assurance conditions will be satisfied; redemption may not occur, but indentures to be discharged if not redeemed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184602,"accession_number":"0000885590-25-000010","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bausch Health launches $4.0B secured notes offering and $3.8B credit facilities to refinance debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Indirect subsidiary launched $4.0B senior secured notes due 2032 to qualified institutional investors.","New senior secured credit facilities: $400M 5-year revolver and $3.4B 5.5-year term loan B, pari passu with notes.","Proceeds to repay secured term loan due 2027, redeem all 2025 and 2027 notes, and redeem 9.000% HoldCo notes due 2028.","Conditional redemption notices: 2025 notes redemption April 18, 2025; 2027/HoldCo notes redemption April 4, 2025.","Redemption conditioned on closing of note offering and term loan funding; no assurances given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184601,"accession_number":"0000885590-25-000004","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch Health reports Q4/FY2024 results but filing lacks specific financial figures","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filed an 8-K on Feb 19, 2025, announcing Q4 and full year 2024 results via press release.","Press release Exhibit 99.1 is referenced but not provided in the filing text; no EPS, revenue, or segment data available.","Management commentary and guidance details cannot be extracted from the appended documents."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":9625000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201181,"accession_number":"0000950103-24-015811","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bausch + Lomb borrows $400M in new term loans maturing May 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Bausch + Lomb added $400M term loans under its credit agreement; proceeds used to repay revolver and for corporate purposes.","Loans mature May 10, 2027, with quarterly amortization: 0.625% of principal for first 8 installments, then 1.875%.","Interest at base rate or term SOFR plus margin: 2.25% (base) or 3.25% (SOFR); other terms unchanged.","Bausch Health (BHC) filed the 8-K; the borrowing is at subsidiary Bausch + Lomb (BLCO)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201180,"accession_number":"0000885590-24-000034","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch Health Q3 2024 results announced; no specific figures in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release attached as Exhibit 99.1 was not included in provided text.","Refer to the full press release for revenue, EPS, and segment performance.","Company reported results for quarter ended September 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":7066000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217201,"accession_number":"0000885590-24-000026","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch Health issues Q2 2024 earnings press release; details not available","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Form 8-K filed August 1, 2024, referencing press release as Exhibit 99.1.","Press release text is not included in the submission; specific financial figures are missing.","No revenue, EPS, or segment data can be extracted from the provided filing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":4556000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217200,"accession_number":"0000950103-24-010257","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Bausch Health appoints Jean-Jacques Charhon as CFO, Aimee Lenar as EVP US Pharma","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jean-Jacques Charhon named CFO effective Aug 19, 2024; base salary $700K, target bonus 60%, equity grants ~$3M.","Charhon receives one-time sign-on cash bonus of $300K and sign-on equity grant of $3.5M (50% RSUs, 50% PSUs).","Interim CFO John Barresi returns to SVP, Controller role; granted $350K retention RSU award vesting over 3 years.","Barresi's enhanced severance extended to Dec 31, 2025; bi-weekly $5K stipend extended to Sep 30, 2024.","Aimee Lenar joined Jul 15, 2024 as EVP US Pharma, leading Salix, Neurology, Generics, Market Access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236976,"accession_number":"0000885590-24-000021","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bausch Health shareholders elect all directors, approve executive compensation and plan amendment at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; each received over 170M votes for, with ~70.9M broker non-votes.","Advisory vote on executive compensation approved: 78.7M for, 5.2M against, 8.4M abstain.","Amendment to 2014 Omnibus Incentive Plan approved: 174.9M for, 8.9M against, 8.4M abstain.","PricewaterhouseCoopers LLP appointed as independent auditor: 252.8M for, 10.4M withheld."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236975,"accession_number":"0000885590-24-000016","cik":885590,"company_name":"Bausch Health Companies Inc.","ticker":"BHC","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bausch Health releases Q1 2024 earnings; no financial details available","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued on May 2, 2024 for quarter ended March 31, 2024.","Full financial results and segment data are not included in the provided text.","Interim CFO John S. Barresi signed the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":2153000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2786128341.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}